Marinus Pharma (NASDAQ: MRNS) reported Q4 EPS of ($0.74), $0.12 worse than the analyst estimate of ($0.62). Revenue for the quarter came in at $7.19 million versus the consensus estimate of $7.97 million.

GUIDANCE:

Marinus Pharma sees FY2024 revenue of $32-34 million, versus the consensus of $42.73 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.